Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for one of its medications. https://t.co/b4EzEu4AXX ...

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, and has compiled detailed reports on more than 1,000 companies [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Key Takeaways REGN shares are down 22.8% YTD due to weak Eylea sales and pipeline disappointments. Eylea faces intense competition from Vabysmo and biosimilars, with HD version uptake still ramping up. Dupixent and new oncology approvals offer some support, but setbacks in COPD and lymphoma drugs persist. Shares of Regeneron Pharmaceuticals, Inc. (REGN) have lost 22.6% year to date against the industry’s growth of 0.6%. The stock has underperformed the medical sector and S&P 500 Index in this timeframe.A ...

Key Takeaways KYMR stock soared 70.7% in 3 months, outperforming its industry and the broader market. A new $750M collaboration with GILD on CDK2 degraders has fueled investor enthusiasm. Despite a Sanofi setback, KYMR earned a $20M milestone and eyes key pipeline advances in 2025-2026.Shares of Kymera (KYMR) have surged 70.7% in the past three months compared with the industry’s gain of 9.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe.This clinical-stage biotec ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants misled investors conc ...

Core Insights - Senti Biosciences, Inc. has appointed Bryan Baum to its Board of Directors, enhancing its leadership team with his extensive entrepreneurial and investment experience [1][3][4] - Bryan Baum is recognized for his successful track record in scaling companies and has invested in notable firms such as SpaceX, OpenAI, and Airbnb, which may provide strategic advantages to Senti Bio [2][3] - The company is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, aiming to address cancer treatments that current drugs cannot [3][5] Company Overview - Senti Bio is a clinical-stage biotechnology company that leverages synthetic biology to engineer Gene Circuits for new medicines, targeting incurable diseases [5] - The company's pipeline includes cell therapies designed to specifically target and kill cancer cells while sparing healthy cells, with preclinical evidence supporting their efficacy in both NK and T cells [5] - Senti Bio is also exploring the potential of Gene Circuits in other disease modalities beyond oncology, indicating a broad scope for future development [5]

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. alleging securities fraud related to the company's gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Sarepta investors who were affected by alleged securities fraud between June 22, 2023, and June 24, 2025 [1]. - The complaint claims that Sarepta made false statements regarding ELEVIDYS, including significant safety risks, failure to detect severe side effects, and the potential halting of trials due to adverse events [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, July 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...